Carregant...
Inhibition of MCM2 enhances the sensitivity of ovarian cancer cell to carboplatin
Chemotherapy is widely used for the treatment of ovarian cancer. Since chemotherapy resistance is the major cause of poor prognosis in patients with ovarian cancer, it is important to identify new methods to improve the efficacy of chemotherapy. Minichromosome maintenance complex component 2 (MCM2),...
Guardat en:
| Publicat a: | Mol Med Rep |
|---|---|
| Autors principals: | , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
D.A. Spandidos
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6691261/ https://ncbi.nlm.nih.gov/pubmed/31322224 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mmr.2019.10477 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|